Promotion of new drugs·biosimilars at KOS annual conference
By Son, Hyung Min | translator Hong, Ji Yeon
24.12.02 05:20:24
가나다라
0
The annual meeting of the Korean Ophthalmological Society (KOS) was held on November 30 over three days
Global pharmaceutical companies have promoted their original pharmaceuticals, Vabysmo·Eylea·Beovu at the event
Kukje Pharm·Samil Pharm showcased their biosimilars to Eylea, Chong Kun Dang showcases its biosimilar to Lucentis
▲The Korean Ophthalmological Society (KOS) held an annual meeting for three days starting on November 30 at Coex.
Korean and international pharmaceutical and biotech industries are fiercely competing for marketing in the market for macular degeneration. Global companies, including Novartis, Roche, and Bayer, and Korean pharmaceutical companies, including Kukje Pharm, Samil Pharm, and Chong Kun Dang, have participated in the annual meeting of the Korean Ophthalmological Society (KOS), held for three days starting on November 30 at Coex in Samsung-dong, Seoul, to showcase their treatments. The treatment for macular degeneration has been dominated by Novartis' Lucentis and Beovu and Bayer's Eylea. The competition intensified with the recent introduction of Roche's new drug, Vabysmo. Additionally, Korean pharmaceutic
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)